Genetic Sources of Subcomponents of Event-Related Potential in the Dimension of Psychosis Analyzed From the B-SNIP Study
Publication: American Journal of Psychiatry
Abstract
Objective:
Biological risk factors underlying psychosis are poorly understood. Biological underpinnings of the dimension of psychosis can be derived using genetic associations with intermediate phenotypes such as subcomponents of auditory event-related potentials (ERPs). Various ERP subcomponent abnormalities in schizophrenia and psychotic bipolar disorder are heritable and are expressed in unaffected relatives, although studies investigating genetic contributions to ERP abnormalities are limited. The authors used a novel parallel independent component analysis (para-ICA) to determine which empirically derived gene clusters are associated with data-driven ERP subcomponents, assuming a complex etiology underlying psychosis.
Method:
The authors examined the multivariate polygenic association of ERP subcomponents from 64-channel auditory oddball data in 144 individuals with schizophrenia, 210 psychotic bipolar disorder probands, and 95 healthy individuals from the multisite Bipolar-Schizophrenia Network on Intermediate Phenotypes study. Data were reduced by principal components analysis to two target and one standard ERP waveforms. Multivariate association of compressed ERP waveforms with a set of 20,329 single-nucleotide polymorphisms (SNPs) (reduced from a 1-million-SNP array) was examined using para-ICA. Genes associated with SNPs were further examined using pathway analysis tools.
Results:
Para-ICA identified four ERP components that were significantly correlated with three genetic components. Enrichment analysis revealed complement immune response pathway and multiple processes that significantly mediate ERP abnormalities in psychosis, including synaptic cell adhesion, axon guidance, and neurogenesis.
Conclusions:
This study identified three genetic components comprising multiple genes mediating ERP subcomponent abnormalities in schizophrenia and psychotic bipolar disorder. The data suggest a possible polygenic structure comprising genes influencing key neurodevelopmental processes, neural circuitry, and brain function mediating biological pathways plausibly associated with psychosis.
The psychosis dimension contains complex, disabling mental illnesses, including schizophrenia, schizoaffective disorder, and psychotic bipolar disorder, and evidence indicates significant overlap of clinical features (1), brain function and structure (2), pharmacological treatment (3), and genetic determinants (4). Psychotic disorders demonstrate high heritability; unaffected family members are at increased risk for all diseases. Studies have implicated shared neurobiological mechanisms of psychosis, including impaired calcium channel activity (5) and synaptic function (6). Although copy number variants account for a small proportion of cases (7), under polygenic models a single gene’s contribution to disease liability is small, but global effects arising from combinations of gene subsets are significant because together they affect specific key neural systems at multiple points (8). Endophenotypes are heritable, state-independent phenotypes intermediate between the causative genes and clinical disease (9).
The auditory oddball event-related potential (ERP) is a noninvasively measured electrical brain response elicited by an external auditory stimulus. The P300 is a major ERP subcomponent visible as endogenous positive voltage deflection ∼300 ms after stimulus presentation. P300 amplitude signifies attention allocation, cognitive information processing, and context updating (10) and is highly heritable (11). Additionally, auditory ERPs comprise N1, N2, and P2 subcomponents that are generated by the auditory cortices and are associated with stimulus characteristics. Multiple studies report P300 amplitude abnormalities (12, 13) in both schizophrenia and psychotic bipolar disorder, suggesting general psychosis biomarker status. Auditory P300 amplitude is a frequently employed schizophrenia candidate endophenotype because it is robustly reduced in patients with schizophrenia and their close relatives (14–16), is highly heritable, is stable across the course of illness, is relatively unaffected by illness exacerbations, and is elicited by a straightforward task performed easily by psychotic patients. P300 amplitude abnormalities in psychotic bipolar disorder may be proband specific (17). Deficits in ERP subcomponents N1, P2, and N2 are observed in schizophrenia patients (18, 19) and their relatives (20). Both N1 and P2 amplitude abnormalities (13) and their endophenotypic status have been less studied in psychotic bipolar disorder.
The P300 amplitude response with a parietal maximum (P3b) has been related to norepinephrine (21) and dopamine neurotransmission (22). Recent studies examining genetic associations of P300 (23, 24) adopted traditional single-nucleotide polymorphism (SNP)-based univariate approaches, such as genome-wide association (GWA). One polygenic association study identified several interacting SNP loci, including rs1045642 in the ABCB1 gene, which has been linked to P300 ERP in healthy individuals (25), plus genes related to dopaminergic, noradrenergic, and signal transduction/amplification pathways. Previous studies (26–29) have documented genetic associations of P300 amplitude deficits with known schizophrenia risk genes, including DISC1, NRG1, and COMT. One study (26) identified rs1045642 as a schizophrenia risk locus.
The univariate GWA approach relates single gene variants to a unitary phenotype. While straightforward, it has two main drawbacks. First, the weak individual effect of common variants prevents most from reaching genome-wide significance, because of numerous multiple comparisons, requiring extremely large samples to gain sufficient statistical power. Second, simultaneous coupling of multiple genes is ignored. To overcome these problems, multivariate association (30) based on parallel independent component analysis (para-ICA) has been developed to model the polygenic architecture (combinatorial gene effects) of complex psychiatric illnesses. Previous para-ICA studies have revealed known and novel gene clusters implicated in Alzheimer’s disease (31) and psychosis (32) based on structural and functional imaging data, respectively.
In the present study, we sought to identify risk genes collectively associated with ERP endophenotypes in psychosis and to determine whether the gene clusters mediate neurophysiological abnormalities in either or both disorders. We hypothesized that para-ICA would identify novel interacting risk gene clusters (likely including known risk genes) mediating plausible physiological pathways that are disturbed in psychosis.
Method
Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) Study
We assessed genotype-phenotype multivariate associations by combining genetic variants and ERP from schizophrenia, schizoaffective disorder, and psychotic bipolar disorder probands and healthy comparison subjects from the B-SNIP study (www.b-snip.org), which was formed to investigate intermediate phenotypes from multiple modalities and their genetic underpinnings in psychosis.
Recruitment
We examined a subset of 620 probands and healthy comparison subjects selected from the overall B-SNIP cohort of ∼2,600 persons (33) who had undergone genotyping and participated in the B-SNIP auditory oddball paradigm. The group of individuals for whom both genotyping and ERP data were available (N=449) included 144 schizophrenia patients, 210 psychotic bipolar disorder patients, and 95 healthy comparison subjects, ages 15–65 years (demographic and clinical information are provided in Table S1 in the data supplement that accompanies the online edition of this article). Depressive and mania subtypes of schizoaffective disorder probands were classified as schizophrenia and psychotic bipolar disorder, respectively. Schizophrenia and psychotic bipolar disorder proband groups were not matched with healthy comparison subjects on age, sex, or ethnicity. Probands’ medications are listed in Table S2 in the data supplement . The study was explained to all participants, and written informed consent was obtained, as approved by the institutional review boards at the participating sites.
Auditory Oddball Paradigm and EEG Data Acquisition
EEG data were collected independently at each site from identical Neuroscan equipment equipped with 64 Ag/AgCl electrodes (Quik-Cap, Compumedics, El Paso, Texas) while subjects were performing an auditory oddball task (see the supplemental text in the data supplement ). Electrode positions were defined according to the international 10-10 EEG system (see Figure S1 in the data supplement ).
SNP Data Collection
Blood was collected from each subject and genomic DNA was extracted. Genetic variants were obtained by genotyping for ∼1 million (1,140,419) target SNPs across the whole genome using the Illumina Human Omni1-Quad chip and BeadArray platform at Genomas, Inc., at Hartford Hospital.
ERP Data Processing
EEG data were artifact rejected, and averaged ERP data were reduced to two targets and one standard component (Figure 1) using spatial principal components analysis (13) (details are provided in the data supplement ).
FIGURE 1. Spatial Topography Associated With Principal Components for Target and Standard Stimulus Conditionsa
a Two targets (parietal and frontal topography) and one standard component (frontal) were derived from principal components analysis of grand average 64-channel data. The time window for each component is between 250 ms before and 720 ms after stimulus onset.
SNP Data Processing
SNP data were converted to discrete numbers and subjected to a quality control process (see Figure S2 in the data supplement ). Stratification bias was corrected using principal-components analysis (see Figure S3 in the data supplement ). Data were reduced from 1 million to 20,329 SNPs by selecting those that were significant at p<0.05 in the logistic regression (see the data supplement ).
Para-ICA-Based SNP-ERP Association
Para-ICA is a multivariate association analysis that links linearly associated functional ERP activity with synergistic gene clusters by relating the hidden structures from both ERP and SNP data. Data were organized as a matrix of 1) subjects by SNPs (449×20,329) and 2) subjects by ERP component waveforms (449×294 [3×98 time points]) and were reduced to 11 and eight components or factors, respectively. ERP and SNP data were jointly processed by para-ICA (25, 30) (see Figure S4 and the supplementary text in the data supplement ).
Correlation and Statistical Analysis
Bimodal feature association using para-ICA was assessed by correlations between SNP and ERP loading coefficients (LCs). Significance levels were adjusted through partial correlation by regressing the effects of age, sex, and site on LCs. Correlations for all component pair combinations (8×11=88) were evaluated, and significance levels were adjusted using Bonferroni multiple comparison correction for number of combinations (p<0.05/88). ERP and SNP LCs of significant component pairs were examined for group differences using t tests. Dominant SNPs and ERP features in the components contributing to the association were identified with a threshold of |Z|=2.5 for both modalities. Supplementary analyses included correlation of ERP LCs with IQ score and antipsychotic dosage in chlorpromazine equivalents.
ERP-Structural MRI Association Analysis
Brain structures (see the supplementary text for details on structural MRI data collection) associated with the ERP components were identified by partial correlation (accounting for age, sex, and site) of regional volumetric measures with ERP loading coefficients. The p values were corrected for multiple comparisons using false discovery rate.
Pathway Analysis
Genes corresponding to SNPs selected from the genetic component were entered into GeneGo’s MetaCore annotation software package (Thomson Reuters, New York) to determine the biological pathways associated with ERP abnormalities (see the supplementary text ).
Results
Gene-ERP Multivariate Linkage
Four (E1, E2, E3, and E6) of the eight independent ERP components were significantly connected to three (G1, G4, and G9) of the 11 genetic/SNP components. ERP component E6 (frontal target P3a) was correlated negatively with G1 (r=−0.23, N=449, p<0.0000007) (Figure 2A), indicating increased loading on G1 related to diminished frontal target P3a. E1 was positively associated with G9 (r=0.24, N=449, p<0.0000006) (Figure 2C), indicating increased loading on G9 related to increased ERP features in E1 (frontal standard N1 and P2, and frontal and parietal target N1). Both E2 (parietal target N2) and E3 (parietal target P3b) components were negatively (r=−0.21, N=449, p<0.000008) and positively (r=0.22, N=449, p<0.000002) correlated (Figure 2B) with the same gene component G4, respectively (Figure 3). Although IQ differed between groups and was negatively correlated with component E3 (r=−0.166, N=446, p<0.0004), controlling its effects did not alter the ERP-SNP correlation. ERP component E2 was positively correlated with antipsychotic dosage in chlorpromazine equivalents (r=0.179, N=215, p=0.009), indicating that higher dosage was associated with increased abnormality. Post hoc comparisons revealed significant differences in ERP and SNP LCs between healthy comparison subjects and both schizophrenia and psychotic bipolar disorder probands for all significantly correlated components (Figure 4). ERP component E6 (frontal target P3a) differed between schizophrenia and psychotic bipolar disorder probands, while other ERP components failed to differentiate the two proband groups. Reliability testing by leave-one-out cross-validation revealed an average within-modality correlation >0.85, indicating stable ERP and SNP components.
FIGURE 2. Event-Related Potential (ERP) Subcomponents and Associated Gene Components Derived From the Multivariate Parallel Independent Component Analysisa
a The figure shows results from an E6-G1 component pair (panel A), E2-G4 and E3-G4 component pairs (panel B), and an E1-G9 component pair (panel C). E6 comprised frontal target P3a subcomponent. E2 and E3 comprised parietal target N2 and P3b subcomponents, respectively. E1 comprised standard N1 and P2, parietal target N1, and frontal target N1 subcomponents. Peak amplitude within predefined time periods poststimulus was used to identify the ERP component. The polarity of the ERP waveforms for N1, N2, and P2 subcomponents is reversed by independent component analysis. Biological pathways and process networks associated with each gene component from enrichment analysis are also displayed.
FIGURE 3. Scatterplots of Loading Coefficients for Schizophrenia and Psychotic Bipolar Disorder Probands and Healthy Comparison Subjectsa
a The overall association between the loading coefficients across the three groups is displayed as the linear fit. ERP=event-related potential; SNP=single-nucleotide polymorphism.
FIGURE 4. Mean Loading Coefficients (LCs) for Significantly Associated Event-Related Potential and Gene Components for Schizophrenia and Psychotic Bipolar Probands and Healthy Comparison Subjectsa
a Post hoc comparisons included pairwise t tests between healthy comparison subjects and schizophrenia and psychotic bipolar disorder probands. Error bars indicate standard deviation. ERP=event-related potential; SNP=single-nucleotide polymorphism.
*p<0.05. **p<0.0001. ***p≪0.000000001.
ERP-Structural Volume Associations
ERP component E1 (frontal standard N1 and P2, and frontal and parietal target N1) was associated with volume reduction in gray matter regions including the pars opercularis, the posterior cingulate, the insula, and the caudal middle frontal, middle temporal, and supramarginal gyri (Table 1). E3 (P3b) was associated with volume reduction in the left entorhinal and hippocampal regions.
| ERP Component and Brain Region | r | p |
|---|---|---|
| E1 | ||
| Left caudal middle frontal gyrus | –0.158 | 0.00238 |
| Left pars opercularis | –0.173 | 0.00086 |
| Left posterior cingulate gyrus | –0.153 | 0.00324 |
| Left insula | –0.158 | 0.00236 |
| Right middle temporal gyrus | –0.152 | 0.00351 |
| Right supramarginal gyrus | –0.148 | 0.00433 |
| E3 | ||
| Left entorhinal cortex | 0.171 | 0.00098 |
| Left hippocampus | 0.167 | 0.00125 |
a A total of 82 brain volumes were extracted for 369 of the 449 subjects for whom ERP data were available, using FreeSurfer. The association was evaluated using partial correlation adjusting for age, sex, and data collection site. ERP component E1 was correlated with six regional volumes (after false discovery rate correction), while E3 was related to two regional volumes. ERP components E2 and E6 did not yield significant correlations after false discovery rate correction.
Pathway Analysis
Prominent process networks that were associated with G1 (related to ERP component E6) included (but were not limited to) neurogenesis-axon guidance and cell adhesion (cadherins, synaptic contact) (see Table S3 in the data supplement ). Major metabolic components included lysophosphatidylserine and sphingomyelin pathways. Functional properties for the top 20 genes from all three genetic components are summarized in Table 2.
| Geneb | SNPc | Chromosome | Position | Z Score | Relative Weight | Functional Attribute |
|---|---|---|---|---|---|---|
| Component G1 | ||||||
| DCC* | rs16956411I | 18q21.2 | 50775428 | –9.93 | 1 | Axon guidance, neuronal migration |
| BOC* | rs775228I | 3q13.2 | 112997554 | –4.84 | 0.487 | Cell adhesion and synaptic development |
| SEC14L2* | rs4820845I | 22q12.2 | 30800338 | –4.50 | 0.461 | Lipid binding |
| PDLIM5* | rs13121500I | 4q22.3 | 95577290 | 4.41 | 0.444 | Regulation of protein kinase C activity; synapse and dendritic spine morphogenesis |
| HDAC9* | rs12699994I | 7p21.1 | 18895297 | –4.31 | 0.434 | Neocortical neuron development by transcriptional regulation |
| MAML3* | rs7678266I | 4q31.1 | 140668374 | –4.23 | 0.426 | Unknown |
| B3GNTL1* | rs1001865I | 17q25.3 | 80914988 | 4.10 | 0.417 | Unknown |
| TBCD* | rs3785520I | 17q25.3 | 80895745 | –4.00 | 0.402 | Captures and stabilizes β-tubulin |
| SNAP91* | rs1546977I | 6q14.2 | 84314423 | –3.96 | 0.399 | Formation of clathrin-coated vesicles at presynaptic membranes |
| LY9 | rs574610Utr-3 | 1q23.3 | 160797684 | –3.91 | 0.384 | Unknown |
| CD244 | rs485618Utr-3 | 1q23.3 | 160800480 | –3.86 | 0.389 | Mediation of non-major histocompatibility complex restricted killing and modulation of natural killer cell cytolysis |
| CDKAL1* | rs7758129I | 6p22.3 | 20609241 | 3.85 | 0.388 | Unknown |
| ESRRG* | rs3929399I | 1q41 | 216718378 | 3.84 | 0.387 | Cell proliferation |
| MCTP2* | rs1655455I | 15q26.2 | 94858686 | –3.83 | 0.386 | Calcium ion binding; intracellular signal transduction |
| PIP4K2A | rs7071450I | 10p12.2 | 22867451 | 3.79 | 0.381 | Cell proliferation and differentiation |
| TMEFF2* | rs10185068I | 2q32.3 | 192924987 | –3.78 | 0.381 | Unknown |
| ZC3H18* | rs12445653I | 16q24.2 | 88677230 | –3.75 | 0.378 | Unknown |
| VWA3B* | rs10211067Utr-5 | 2q11.2 | 98703659 | –3.73 | 0.376 | Unknown |
| RASGRP3 | rs11687777I | 2p22.3 | 33764709 | –3.66 | 0.368 | Signal transduction |
| ANKIB1 | rs721015I | 7q21.2 | 91925256 | –3.59 | 0.361 | Unknown |
| Component G4 | ||||||
| MSRA* | rs7459532I | 8p23.1 | 10261068 | –7.96 | 1 | Enzymatic reduction of methionine sulfoxide and repair of oxidative damage |
| XKR6* | rs2409691I | 8p23.1 | 10943276 | –7.30 | 0.917 | Unknown |
| RP1L1 | rs7386213I | 8p23.1 | 10503525 | –6.47 | 0.813 | Binds to microtubules; regulation of microtubule polymerization |
| BLK | rs2618451I | 8p23.1 | 11376266 | –6.32 | 0.794 | Cell proliferation and differentiation |
| TNKS* | rs7840706I | 8p23.1 | 9535056 | –5.39 | 0.677 | Unknown |
| TPO* | rs2276702I | 2p25.3 | 1426621 | –5.06 | 0.635 | Iodination of tyrosine residues in thyroglobulin |
| IL1F10* | rs6761276M | 2q13 | 113832312 | –5.04 | 0.632 | Regulation of innate immune responses |
| MFHAS1* | rs4841044I | 8p23.1 | 8664940 | 5.00 | 0.628 | Unknown |
| ADAMTS16* | rs270178I | 5p15.32 | 5165415 | 4.65 | 0.584 | Unknown |
| DOCK8* | rs10967788I | 9p24.3 | 282180 | –4.62 | 0.580 | Interacts with Rho GTPases, intracellular signaling networks |
| TAF8 | rs6917299I | 6p21.1 | 42025058 | –4.04 | 0.508 | Involved in transcription factors |
| GSG1L* | rs1645362I | 16p12.1 | 27891473 | –4.04 | 0.508 | Unknown |
| ODZ3* | rs957053I | 4q35.1 | 183248389 | –4.04 | 0.508 | Unknown |
| VAT1L* | rs9933953I | 16q23.1 | 77909692 | 4.02 | 0.507 | Unknown |
| USH2A* | rs17025267I | 1q41 | 215903907 | 3.97 | 0.495 | Development and homeostasis of inner ear |
| COL2A1* | rs1793923I | 12q13.11 | 48384122 | 3.95 | 0.498 | Unknown |
| INPP5K* | rs1109303I | 17p13.3 | 1403477 | 3.92 | 0.496 | Regulation of actin cytoskeleton |
| NRXN3* | rs10782463I | 14q24.3 | 78978482 | –3.92 | 0.492 | Receptors and synaptic cell adhesion molecules in CNS |
| PNPLA1* | rs12197079M | 6p21.31 | 36274153 | 3.85 | 0.483 | Lipid metabolism (lipolytic and acyltransferase) |
| PKP3 | rs7105848I | 11p15.5 | 396546 | 3.83 | 0.481 | Links cadherins to intermediate cytoskeleton filaments |
| Component G9 | ||||||
| ME1* | rs1170348I | 6q14.2 | 84020324 | –6.90 | 1 | Fatty acid biosynthesis and brain CO2 fixation |
| PEMT* | rs11078389I | 17p11.2 | 17478352 | 5.60 | 0.812 | Synthesizes membrane phospholipids; affects choline levels |
| GPC6* | rs4369513I | 13q31.3 | 94958719 | 5.42 | 0.786 | Cell growth, cell division, and CNS synapse formation |
| SNAP91* | rs217291I | 6q14.2 | 84393942 | 5.38 | 0.78 | (See section G1, above) |
| DLGAP1* | rs1465947I | 18p11.31 | 3973509 | 4.76 | 0.69 | Molecular organization of synapses and neuronal cell signaling |
| PRSS35 | rs592911I | 6q14.2 | 84223563 | –4.47 | 0.648 | Unknown |
| PCSK5* | rs2842467I | 9q21.13 | 78938628 | –4.32 | 0.626 | Mediation of posttranslational endoproteolytic processing for several integrin alpha subunits |
| FRK* | rs12662901I | 6q22.1 | 116305637 | 4.24 | 0.615 | Tyrosine kinase role in cell cycle and growth suppression |
| KCTD8* | rs2020159I | 4p13 | 44330067 | 4.23 | 0.613 | Unknown |
| PDLIM1* | rs11593722I | 10q24.1 | 97006105 | –4.13 | 0.599 | Regulation of actin cytoskeleton dynamics and neurite growth |
| CYP2C19* | rs10786172I | 10q23.33 | 96581094 | 4.08 | 0.591 | Drug metabolism and cholesterol synthesis |
| ANO2* | rs1035066I | 12p13.31 | 5756592 | –4.08 | 0.591 | Unknown |
| SRRM4 | rs1405050I | 12q24.23 | 119443713 | –4.05 | 0.586 | Unknown |
| YSK4* | rs4953941I | 2q21.3 | 135727531 | –4.03 | 0.584 | Unknown |
| CNTNAP2* | rs700281I | 7q35 | 146192877 | 4.03 | 0.584 | CNS cell-to-cell interaction |
| PRDM16* | rs1798246I | 16q24.2 | 3080855 | –4.02 | 0.583 | Unknown |
| TNNI1 | rs3767548I | 1p36.32 | 201388148 | –3.98 | 0.577 | Regulation of calcium ion sensitivity of muscle myofibril contractile apparatus |
| GLT1D1* | rs516034I | 12q24.33 | 129459959 | 3.98 | 0.576 | Unknown |
| ESRRG* | rs1833036I | 1q41 | 216707012 | –3.86 | 0.359 | (See section G1, above) |
| ZNF385B* | rs10432487I | 2q31.2 | 180512804 | 3.85 | 0.558 | Unknown |
a Only the single-nucleotide polymorphism (SNP) with maximal loading within each gene is listed in the table (most genes were represented by several SNPs). Relative weights indicate normalized Z scores, that is, absolute Z score divided by the maximum absolute SNP weight. SNP locations are based on GRCh37/hg19 assembly.
b
An asterisk (*) indicates multiple SNP occurrences (>2) of the gene within the genetic network.
c
Superscript notations are defined as follows: I=intronic; M=missense; Utr-3=three prime untranslated region; Utr-5=five prime untranslated region.
Process networks (collection of coordinated genes controlling biological processes) associated with G4 were cell adhesion (synaptic contact, cadherins, and amyloid proteins) and development neurogenesis (synaptogenesis). Several metabolic networks enriched for genes in G4 included (but were not limited to) N-acyl-sphingosine phosphate, lysophosphatidylserine, phosphatidic acid, and ceramide pathways. Gene component G9 (related to ERP component E1) was significantly (after false discovery rate correction) enriched with immune response genes (classical, alternative, and lectin-induced complements) and G-protein signaling (RhoA regulation). Primary process networks related to G9 were cell adhesion (synaptic contact, cadherins) and the inflammation-complement system. The pathways, known diseases, and major human brain regions from the Allen Brain Atlas (www.brain-map.org) (assessed based on expression Z scores) that were associated with the top 20 genes are listed in Table S4 in the data supplement .
Discussion
The etiological mechanisms for schizophrenia and psychotic bipolar disorder are complex, but one approach to gaining insight into them is to examine biological measures such as ERP that are putatively close to the genetic variation. Currently, the neural substrates and genetic basis for eliciting ERP components are unknown. Various ERP subcomponents demonstrate significant heritability, suggesting strong genetic influences. As a preliminary step, we investigated polygenic sources underlying abnormal ERP subcomponents in the psychosis dimension from a large multisite data set including all probands, based on multivariate association. Additionally, we compared schizophrenia and psychotic bipolar disorder probands against healthy comparison subjects based on DSM criteria.
ERP Components
ERP component E1 (a linear combination of standard N1 and P2 and frontal and parietal target N1) showed overall increased loadings (less change from baseline) in schizophrenia and psychotic bipolar disorder compared with healthy comparison subjects, reflecting deficits in early sensory processing, consistent with previous studies in schizophrenia (18, 20, 34) and psychotic bipolar disorder (13). The primary source of N1 and P2 is the auditory cortex (35, 36) (Heschl’s gyrus); we identified reduction in gray matter regions surrounding this structure. Parietal target N2 in E2 was significantly increased (reduced change from baseline) in probands, indexing abnormal stimulus classification (37). Psychosis probands exhibited decreased frontal target P3a in E6 and parietal target P3b in E3, consistent with previous findings (12). The role of the hippocampus in P3b generation is debated (38); however, our finding of P3b amplitude reduction associated with lower hippocampal volume is consistent with previous evidence (39).
Gene Components
Para-ICA identified gene groups comprising interacting genes with a weight associated with each linkage-contributing gene. We discuss here the genetic underpinnings of ERP abnormalities based on the functionality of top-ranking and frequently appearing genes in each component and biological properties associated with the gene clusters. Of all unique genes pooled across the three genetic components found in this study (N=376), 76 have previously been identified as risk genes for schizophrenia, psychotic bipolar disorder, or both, while we report 300 new genes associated with ERP alterations in psychosis.
G1
Top genes and those identified repeatedly.
The highest-ranking gene in G1 was DCC, encoding a netrin-1 receptor (40) and a novel schizophrenia candidate risk gene (41). Multiple intronic SNPs (27 occurrences in the top 50) within DCC were associated with frontal target P3a in E6. The dominant SNP loading was negative, with a negative correlation between G1 and E6, indicating decreased minor allele frequency associated with increased frontal target P3a. DCC plays a critical role in neuronal circuitry, modulating synaptic connectivity by mediating brain development via axon guidance and dendrite growth (42), with roles in functional reorganization of mesocortical dopamine circuitry (43). DCC is also involved in the development of brain lateralization (44), which is abnormal in schizophrenia (45).
Several intronic SNPs within the BOC gene were found in G1. BOC is the receptor for the molecule Sonic Hedgehog, which plays a critical role in the spatial specificity of synapse formation (46) and guides the formation of cortical microcircuits (47) and dorsoventral axon patterning (48). Multiple SNPs within PDLIM5 encoding the LIM domain protein were detected in G1. PDLIM5 is a candidate risk gene for schizophrenia, psychotic bipolar disorder, and major depression and interacts with brain neuronal N-type calcium channel and protein kinase-C (49). Postsynaptic density proteins containing PDZ domain with protein-binding modules interact with glutamate receptors to regulate synaptic plasticity (50, 51). The HDAC9 gene encoding the histone deacetylase 9 enzyme, which is involved in transcriptional regulation and cell cycle progression, is a known schizophrenia risk gene (52), is pivotal in neocortical neuron development through transcription regulation via histone modification, and regulates dendritic growth in developing cortical neurons (53). HDAC inhibitors modulate cell lineage differentiation during brain development (52) and are direct targets of valproic acid (54) (a mood stabilizer used to treat psychotic bipolar disorder) and may affect antipsychotic response (55). Several SNPs within DISC1, a known schizophrenia risk gene, were found in G1 but were not ranked in the top 20.
Pathways, process, and metabolic networks.
Neurogenesis (in particular axon guidance) and cell adhesion (cadherins and synaptic contact) were the enriched functional processes associated with gene clusters in G1 engaged in modulating frontal target P3a abnormality common to psychosis, indicating that these processes are general psychosis risk mediators. Adult neurogenesis likely plays essential roles in both brain function (56) and the pathophysiology of psychiatric illnesses (57, 58). The primary neurogenesis-axon guidance-associated genes are PCSK5, CACNA1C, DCC, SLIT3, UNC5C, SLIT1, DISC1, NCAM1, NTRK3, ROBO2, GDA, and PLCB1; of these, several are implicated in psychosis risk.
Another key process identified was cell adhesion mediated by cadherins and synaptic contact. Cadherins depend on calcium ion function to facilitate cell adhesion involved in intracellular signaling, memory formation, neuronal migration, synapse formation, and maturation (59), associated with neuropsychiatric disorders. Genes associated with cadherin-based cell adhesion were CTNND2, PTPRJ, PCDH15, PDZK3, CTNNA2, CDH12, VAV2, CDH13, and WNT5B. Several of these are implicated in multiple psychiatric disorders; in particular, CDH12 is associated with psychosis. Synaptic cell adhesion molecules mediate neural connections and synapse development. Such genes were SYT9, NRXN3, CTNND2, GRIN2B, CTNNA2, NCAM1, and OBCAM, of which NRXN3 is implicated in schizophrenia and NCAM1 and GRIN2B in both schizophrenia and psychotic bipolar disorder. Sphingomyelin is a signal transduction system that affects neural tissue and neuronal membrane integrity, which suggests that sphingolipid metabolism may play a key role in the pathogenesis of neuropsychiatric disorders (60).
G4
Top genes and those identified repeatedly.
The most significant G4 candidate gene (associated with parietal target N2 and P3b) was MSRA, a gene that shields against oxidative stress and is associated with schizophrenia susceptibility (61–63). Oxidative stress is important in schizophrenia pathophysiology (64), associated with hypoactive N-methyl-d-aspartate glutamate receptors (65). The chromosome region 8p23.1, in particular SNP D8S542 within MSRA, is strongly associated with both schizophrenia and psychotic bipolar disorder (66, 67).
Pathways, process, and metabolic networks.
Developmental neurogenesis, synaptogenesis, and cell adhesion was the significant process network mediating psychosis risk through parietal P3b and N2 abnormalities. Metabolic processes including lysophosphatidylserine, phosphatidic acid, and ceramide networks regulate P3b and N2 abnormalities in schizophrenia and psychotic bipolar disorder. Phospholipids constitute cell membranes regulating signal transduction and acting as key secondary messengers. Abnormal phospholipid distribution occurs in schizophrenia in the prefrontal cortex (68). Both calcium-independent and calcium-dependent phospholipase A2 enzymes are abnormal in schizophrenia (69, 70). Ceramides are lipid signaling molecules guiding cellular differentiation, proliferation, and apoptosis altered in both first-episode schizophrenia (71) and depression.
G9
Top genes and those identified repeatedly.
Multiple SNPs were identified in the ME1 gene encoding the cytosolic, NADP-dependent malic enzyme involved in metabolic pathways. No direct evidence from previous studies suggests ME1’s role in schizophrenia and psychotic bipolar disorder, except for increased postmortem expression in the brain in unmedicated patients with bipolar disorder (72) and linkage signals in schizophrenia in the vicinity of ME1 (73). The PEMT gene encodes for an enzyme synthesizing membrane phospholipids associated with schizophrenia (74). This gene helps mediate arachidonic acid signaling, neuronal differentiation, and neurite growth (75). The GPC6 gene belongs to the glypicans that promote glutamate receptor clustering and receptivity and induce postsynaptic synapse formation (76). SNAP91 encodes for clathrin coat assembly protein 180, which is enriched in presynaptic neuronal terminals (77). SNAP91 is involved in intracellular signaling (78) associated with the Wnt pathway (79) and is implicated in psychotic bipolar disorder (80).
Pathways, process, and metabolic networks.
Multiple immune response pathways were associated with psychosis risk mediated by frontal, parietal target N1 and standard N1, and P2 ERP abnormalities in probands, suggesting the immune system’s role in the pathogenesis of psychosis (81), consistent with previous schizophrenia studies (82, 83). The classical complement pathway acts on synapse remodeling, pruning, neuronal plasticity, and neurodevelopmental processes via immune system cells and molecules (C3) (84) and is implicated in the pathophysiology of neurodegenerative disorders (85, 86). This study implicated immune system CR2 and C3 genes. The latter, a schizophrenia risk gene (87), is involved in synapse development and regulates neuronal connectivity (88). Gene component G9 was associated with cell adhesion regulated by cadherins and synaptic contact, which is relevant to schizophrenia and psychotic bipolar disorder risk.
We did not conduct replication analyses to validate the present findings; however, several candidate genes and processes identified in this study have previously been implicated in schizophrenia and psychotic bipolar disorder, supporting the neurodevelopmental hypothesis of schizophrenia (89) and affective disorders (90). Our findings point to converging evidence from pathway-based studies that have identified similar biological mechanisms associated with schizophrenia risk, including axon guidance (91–93), cell adhesion (94, 95), inflammation, and the immune system (96). A recent resting functional MRI-genetic study from B-SNIP using para-ICA (32) identified similar processes, including developmental neurogenesis, axon guidance, synaptic and cadherin cell adhesion, immune response, nervous system development, and ceramide and sphingosine pathways mediating aberrant default mode activity in psychosis. These data help confirm the present findings and validate the approach undertaken to merge functional and genetic data to dissect the complex mechanisms mediating biological phenotypes in these disorders. A complete overlap in pathways and processes across diverse phenotypes is unlikely, as they probably probe different domains of neurophysiology in these disorders.
Strengths and Limitations
Advantages of this study include our use of high-density spatial ERP data in a large multisite psychosis sample. Limitations included unmatched age, sex, and sample sizes between groups, which we adjusted for by controlling their effects through partial correlation between the SNP and ERP loading coefficients; multisite effects were accounted for by regressing data collection site. The ERP phenotypes we examined may be influenced by medication; it was not straightforward to control for medication effects because probands were on numerous medications and had varying illness chronicity, severity, and duration. Our findings could not be validated because of the lack of a replication sample. Para-ICA was optimized by selecting nominally disease-associated SNPs from univariate analysis. Thus, other genetic networks that may be weakly associated with the ERP subcomponents were overlooked.
Conclusions
As hypothesized, we derived both novel interacting candidate genes and known schizophrenia and psychotic bipolar disorder risk genes mediating ERP abnormalities in psychosis. In general, our data suggest a strong multifactorial genetic component comprising brain-relevant genes that play a key role in neural functions, specifically those controlling neuronal circuits and neurodevelopmental processes. We identified one genetic cluster enriched with genes for neurogenesis-related axon guidance mediating psychosis risk via frontal target P3a abnormalities in probands. The second genetic component was enriched with genes involved in developmental neurogenesis-synaptogenesis, and ceramide and phospholipid networks, influencing P3b abnormalities in psychosis. The third genetic component comprised genes coding for the complement immune response pathway associated with schizophrenia and psychotic bipolar disorder risk through standard N1, P2, and frontal and parietal target N1 abnormalities. All three genetic components mediated ERP abnormalities across the psychosis dimension. Cell adhesion mediated by synaptic contact and cadherins was the prominent network process driving all the ERP abnormalities in psychoses.
Footnote
Dr. Ruaño is president and founder of Genomas, Inc. Dr. Tamminga is a Deputy Editor at the Journal; she has received research support from Sunovion and travel funds from Autiphony Therapeutics and has served as a consultant for Astellas, Eli Lilly, Kaye Scholer LLC for Pfizer, and Lundbeck. Dr. Sweeney has received support from Bristol-Myers Squibb, Eli Lilly, Janssen, Roche, and Takeda. Dr. Keshavan has received support from Sunovion. The other authors report no financial relationships with commercial interests.
Supplementary Material
File (appi.ajp.2014.13101411.ds001.pdf)
- View/Download
- 1000.51 KB
References
1.
Hill SK, Reilly JL, Harris MS, et al: A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia. Schizophr Res 2009; 113:167–175
2.
Chai XJ, Whitfield-Gabrieli S, Shinn AK, et al: Abnormal medial prefrontal cortex resting-state connectivity in bipolar disorder and schizophrenia. Neuropsychopharmacology 2011; 36:2009–2017
3.
Carpenter WT, Bustillo JR, Thaker GK, et al: The psychoses: cluster 3 of the proposed meta-structure for DSM-V and ICD-11. Psychol Med 2009; 39:2025–2042
4.
Bramon E, Sham PC: The common genetic liability between schizophrenia and bipolar disorder: a review. Curr Psychiatry Rep 2001; 3:332–337
5.
Smoller JW, Craddock N, Kendler K, et al: Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013; 381:1371–1379
6.
Eastwood SL, Harrison PJ: Hippocampal synaptic pathology in schizophrenia, bipolar disorder, and major depression: a study of complexin mRNAs. Mol Psychiatry 2000; 5:425–432
7.
Grozeva D, Kirov G, Ivanov D, et al: Rare copy number variants: a point of rarity in genetic risk for bipolar disorder and schizophrenia. Arch Gen Psychiatry 2010; 67:318–327
8.
Purcell SM, Wray NR, Stone JL, et al: Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460:748–752
9.
Gottesman II, Gould TD: The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160:636–645
10.
Polich J: Updating P300: an integrative theory of P3a and P3b. Clin Neurophysiol 2007; 118:2128–2148
11.
van Beijsterveldt CE, van Baal GC, Molenaar PC, et al: Stability of genetic and environmental influences on P300 amplitude: a longitudinal study in adolescent twins. Behav Genet 2001; 31:533–543
12.
O’Donnell BF, Vohs JL, Hetrick WP, et al: Auditory event-related potential abnormalities in bipolar disorder and schizophrenia. Int J Psychophysiol 2004; 53:45–55
13.
Ethridge LE, Hamm JP, Shapiro JR, et al: Neural activations during auditory oddball processing discriminating schizophrenia and psychotic bipolar disorder. Biol Psychiatry 2012; 72:766–774
14.
Winterer G, Egan MF, Raedler T, et al: P300 and genetic risk for schizophrenia. Arch Gen Psychiatry 2003; 60:1158–1167
15.
Turetsky BI, Cannon TD, Gur RE: P300 subcomponent abnormalities in schizophrenia, III: deficits in unaffected siblings of schizophrenic probands. Biol Psychiatry 2000; 47:380–390
16.
Bestelmeyer PE, Phillips LH, Crombie C, et al: The P300 as a possible endophenotype for schizophrenia and bipolar disorder: evidence from twin and patient studies. Psychiatry Res 2009; 169:212–219
17.
Schulze KK, Hall MH, McDonald C, et al: Auditory P300 in patients with bipolar disorder and their unaffected relatives. Bipolar Disord 2008; 10:377–386
18.
Salisbury DF, Collins KC, McCarley RW: Reductions in the N1 and P2 auditory event-related potentials in first-hospitalized and chronic schizophrenia. Schizophr Bull 2010; 36:991–1000
19.
O’Donnell BF, Shenton ME, McCarley RW, et al: The auditory N2 component in schizophrenia: relationship to MRI temporal lobe gray matter and to other ERP abnormalities. Biol Psychiatry 1993; 34:26–40
20.
Foxe JJ, Yeap S, Snyder AC, et al: The N1 auditory evoked potential component as an endophenotype for schizophrenia: high-density electrical mapping in clinically unaffected first-degree relatives, first-episode, and chronic schizophrenia patients. Eur Arch Psychiatry Clin Neurosci 2011; 261:331–339
21.
Nieuwenhuis S, Aston-Jones G, Cohen JD: Decision making, the P3, and the locus coeruleus-norepinephrine system. Psychol Bull 2005; 131:510–532
22.
Pogarell O, Padberg F, Karch S, et al: Dopaminergic mechanisms of target detection: P300 event related potential and striatal dopamine. Psychiatry Res 2011; 194:212–218
23.
Mulert C, Juckel G, Giegling I, et al: A Ser9Gly polymorphism in the dopamine D3 receptor gene (DRD3) and event-related P300 potentials. Neuropsychopharmacology 2006; 31:1335–1344
24.
Tsai SJ, Yu YW, Chen TJ, et al: Association analysis for dopamine D3 receptor, dopamine D4 receptor, and dopamine transporter genetic polymorphisms and P300 event-related potentials for normal young females. Psychiatr Genet 2003; 13:51–53
25.
Liu J, Kiehl KA, Pearlson G, et al: Genetic determinants of target and novelty-related event-related potentials in the auditory oddball response. Neuroimage 2009; 46:809–816
26.
Decoster J, De Hert M, Viechtbauer W, et al: Genetic association study of the P300 endophenotype in schizophrenia. Schizophr Res 2012; 141:54–59
27.
Bramon E, Dempster E, Frangou S, et al: Neuregulin-1 and the P300 waveform: a preliminary association study using a psychosis endophenotype. Schizophr Res 2008; 103:178–185
28.
Gallinat J, Bajbouj M, Sander T, et al: Association of the G1947A COMT (Val(108/158)Met) gene polymorphism with prefrontal P300 during information processing. Biol Psychiatry 2003; 54:40–48
29.
Blackwood DH, Fordyce A, Walker MT, et al: Schizophrenia and affective disorders: cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am J Hum Genet 2001; 69:428–433
30.
Liu J, Demirci O, Calhoun VD: A parallel independent component analysis approach to investigate genomic influence on brain function. IEEE Signal Process Lett 2008; 15:413–416
31.
Meda SA, Narayanan B, Liu J, et al: A large scale multivariate parallel ICA method reveals novel imaging-genetic relationships for Alzheimer’s disease in the ADNI cohort. Neuroimage 2012; 60:1608–1621
32.
Meda SA, Ruaño G, Windemuth A, et al: Multivariate analysis reveals genetic associations of the resting default mode network in psychotic bipolar disorder and schizophrenia. Proc Natl Acad Sci USA 2014; 111:E2066–E2075
33.
Tamminga CA, Ivleva EI, Keshavan MS, et al: Clinical phenotypes of psychosis in the Bipolar and Schizophrenia Network on Intermediate Phenotypes (B-SNIP). Am J Psychiatry 2013; 170:1263–1274
34.
Leavitt VM, Molholm S, Ritter W, et al: Auditory processing in schizophrenia during the middle latency period (10–50 ms): high-density electrical mapping and source analysis reveal subcortical antecedents to early cortical deficits. J Psychiatry Neurosci 2007; 32:339–353
35.
Liem F, Zaehle T, Burkhard A, et al: Cortical thickness of supratemporal plane predicts auditory N1 amplitude. Neuroreport 2012; 23:1026–1030
36.
Näätänen R, Picton T: The N1 wave of the human electric and magnetic response to sound: a review and an analysis of the component structure. Psychophysiology 1987; 24:375–425
37.
Näätänen R, Picton TW: N2 and automatic versus controlled processes. Electroencephalogr Clin Neurophysiol Suppl 1986; 38:169–186
38.
Polich J, Criado JR: Neuropsychology and neuropharmacology of P3a and P3b. Int J Psychophysiol 2006; 60:172–185
39.
Dutt A, Ganguly T, Shaikh M, et al: Association between hippocampal volume and P300 event related potential in psychosis: support for the Kraepelinian divide. Neuroimage 2012; 59:997–1003
40.
Mehlen P, Furne C: Netrin-1: when a neuronal guidance cue turns out to be a regulator of tumorigenesis. Cell Mol Life Sci 2005; 62:2599–2616
41.
Grant A, Fathalli F, Rouleau G, et al: Association between schizophrenia and genetic variation in DCC: a case-control study. Schizophr Res 2012; 137:26–31
42.
Zhang C, Gao J, Zhang H, et al: Robo2–slit and Dcc–netrin1 coordinate neuron axonal pathfinding within the embryonic axon tracts. J Neurosci 2012; 32:12589–12602
43.
Grant A, Hoops D, Labelle-Dumais C, et al: Netrin-1 receptor-deficient mice show enhanced mesocortical dopamine transmission and blunted behavioural responses to amphetamine. Eur J Neurosci 2007; 26:3215–3228
44.
Srour M, Rivière JB, Pham JM, et al: Mutations in DCC cause congenital mirror movements. Science 2010; 328:592
45.
Shirakawa O, Kitamura N, Lin XH, et al: Abnormal neurochemical asymmetry in the temporal lobe of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25:867–877
46.
Courchet J, Polleux F: Sonic hedgehog, BOC, and synaptic development: new players for an old game. Neuron 2012; 73:1055–1058
47.
Harwell CC, Parker PR, Gee SM, et al: Sonic hedgehog expression in corticofugal projection neurons directs cortical microcircuit formation. Neuron 2012; 73:1116–1126
48.
Connor RM, Allen CL, Devine CA, et al: BOC, brother of CDO, is a dorsoventral axon-guidance molecule in the embryonic vertebrate brain. J Comp Neurol 2005; 485:32–42
49.
Maeno-Hikichi Y, Chang S, Matsumura K, et al: A PKC epsilon-ENH-channel complex specifically modulates N-type Ca2+ channels. Nat Neurosci 2003; 6:468–475
50.
Remedios R, Subramanian L, Tole S: LIM genes parcellate the embryonic amygdala and regulate its development. J Neurosci 2004; 24:6986–6990
51.
Jeleń F, Oleksy A, Smietana K, et al: PDZ domains: common players in the cell signaling. Acta Biochim Pol 2003; 50:985–1017
52.
Lang B, Alrahbeni TM, Clair DS, et al: HDAC9 is implicated in schizophrenia and expressed specifically in post-mitotic neurons but not in adult neural stem cells. Am J Stem Cells 2012; 1:31–41
53.
Sugo N, Oshiro H, Takemura M, et al: Nucleocytoplasmic translocation of HDAC9 regulates gene expression and dendritic growth in developing cortical neurons. Eur J Neurosci 2010; 31:1521–1532
54.
Phiel CJ, Zhang F, Huang EY, et al: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276:36734–36741
55.
Kurita M, Holloway T, García-Bea A, et al: HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nat Neurosci 2012; 15:1245–1254
56.
Spalding KL, Bergmann O, Alkass K, et al: Dynamics of hippocampal neurogenesis in adult humans. Cell 2013; 153:1219–1227
57.
Eisch AJ, Cameron HA, Encinas JM, et al: Adult neurogenesis, mental health, and mental illness: hope or hype? J Neurosci 2008; 28:11785–11791
58.
Toro CT, Deakin JF: Adult neurogenesis and schizophrenia: a window on abnormal early brain development? Schizophr Res 2007; 90:1–14
59.
Stănescu L, Georgescu G, Zaharescu J, et al: [Dynamic aspects of blood gastrin after antral stimulation.] Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna 1978; 30:311–318 (Romanian)
60.
Keshavan MS, Mallinger AG, Pettegrew JW, et al: Erythrocyte membrane phospholipids in psychotic patients. Psychiatry Res 1993; 49:89–95
61.
Walss-Bass C, Soto-Bernardini MC, Johnson-Pais T, et al: Methionine sulfoxide reductase: a novel schizophrenia candidate gene. Am J Med Genet B Neuropsychiatr Genet 2009; 150B:219–225
62.
Ma X, Deng W, Liu X, et al: A genome-wide association study for quantitative traits in schizophrenia in China. Genes Brain Behav 2011; 10:734–739
63.
Yao JK, Keshavan MS: Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxid Redox Signal 2011; 15:2011–2035
64.
Flatow J, Buckley P, Miller BJ: Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry 2013; 74:400–409
65.
Stahl SM: Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. CNS Spectr 2007; 12:265–268
66.
Kaufmann CA, Suarez B, Malaspina D, et al: NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigrees. Am J Med Genet 1998; 81:282–289
67.
Ophoff RA, Escamilla MA, Service SK, et al: Genomewide linkage disequilibrium mapping of severe bipolar disorder in a population isolate. Am J Hum Genet 2002; 71:565–574
68.
Matsumoto J, Sugiura Y, Yuki D, et al: Abnormal phospholipids distribution in the prefrontal cortex from a patient with schizophrenia revealed by matrix-assisted laser desorption/ionization imaging mass spectrometry. Anal Bioanal Chem 2011; 400:1933–1943
69.
Law MH, Cotton RG, Berger GE: The role of phospholipases A2 in schizophrenia. Mol Psychiatry 2006; 11:547–556
70.
Ross BM, Hughes B, Kish SJ, et al: Serum calcium-independent phospholipase A2 activity in bipolar affective disorder. Bipolar Disord 2006; 8:265–270
71.
Smesny S, Schmelzer CE, Hinder A, et al: Skin ceramide alterations in first-episode schizophrenia indicate abnormal sphingolipid metabolism. Schizophr Bull 2013; 39:933–941
72.
Iwamoto K, Bundo M, Kato T: Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet 2005; 14:241–253
73.
Lee BD, Walss-Bass C, Thompson PM, et al: Malic enzyme 2 and susceptibility to psychosis and mania. Psychiatry Res 2007; 150:1–11
74.
Liu Y, Zhang H, Ju G, et al: A study of the PEMT gene in schizophrenia. Neurosci Lett 2007; 424:203–206
75.
Paoletti L, Elena C, Domizi P, et al: Role of phosphatidylcholine during neuronal differentiation. IUBMB Life 2011; 63:714–720
76.
Allen NJ, Bennett ML, Foo LC, et al: Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors. Nature 2012; 486:410–414
77.
Yao PJ, Coleman PD, Calkins DJ: High-resolution localization of clathrin assembly protein AP180 in the presynaptic terminals of mammalian neurons. J Comp Neurol 2002; 447:152–162
78.
Cho JH, Oh DY, Kim HJ, et al: The TSP motif in AP180 inhibits phospholipase D1 activity resulting in increased efficacy of anticancer drug via its direct binding to carboxyl terminal of phospholipase D1. Cancer Lett 2011; 302:144–154
79.
Kohn AD, Moon RT: Wnt and calcium signaling: beta-catenin-independent pathways. Cell Calcium 2005; 38:439–446
80.
Goes FS, Hamshere ML, Seifuddin F, et al: Genome-wide association of mood-incongruent psychotic bipolar disorder. Transl Psychiatr 2012; 2:e180
81.
Mayilyan KR, Weinberger DR, Sim RB: The complement system in schizophrenia. Drug News Perspect 2008; 21:200–210
82.
Håvik B, Le Hellard S, Rietschel M, et al: The complement control-related genes CSMD1 and CSMD2 associate to schizophrenia. Biol Psychiatry 2011; 70:35–42
83.
Schizophrenia Working Group of the Psychiatric Genomics Consortium: Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014; 511:421–427
84.
Stephan AH, Barres BA, Stevens B: The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci 2012; 35:369–389
85.
Maier M, Peng Y, Jiang L, et al: Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci 2008; 28:6333–6341
86.
Weksler ME, Gouras G, Relkin NR, et al: The immune system, amyloid-beta peptide, and Alzheimer’s disease. Immunol Rev 2005; 205:244–256
87.
Rudduck C, Beckman L, Franzén G, et al: C3 and C6 complement types in schizophrenia. Hum Hered 1985; 35:255–258
88.
Boulanger LM: Immune proteins in brain development and synaptic plasticity. Neuron 2009; 64:93–109
89.
Owen MJ, O’Donovan MC, Thapar A, et al: Neurodevelopmental hypothesis of schizophrenia. Br J Psychiatry 2011; 198:173–175
90.
Guilmatre A, Dubourg C, Mosca AL, et al: Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. Arch Gen Psychiatry 2009; 66:947–956
91.
Gilman SR, Chang J, Xu B, et al: Diverse types of genetic variation converge on functional gene networks involved in schizophrenia. Nat Neurosci 2012; 15:1723–1728
92.
Greenwood TA, Lazzeroni LC, Murray SS, et al: Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry 2011; 168:930–946
93.
Greenwood TA, Light GA, Swerdlow NR, et al: Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS ONE 2012; 7:e29630
94.
O’Dushlaine C, Kenny E, Heron E, et al: Molecular pathways involved in neuronal cell adhesion and membrane scaffolding contribute to schizophrenia and bipolar disorder susceptibility. Mol Psychiatry 2011; 16:286–292
95.
Juraeva D, Haenisch B, Zapatka M, et al: Integrated pathway-based approach identifies association between genomic regions at CTCF and CACNB2 and schizophrenia. PLoS Genet 2014; 10:e1004345
96.
Jia P, Wang L, Meltzer HY, et al: Common variants conferring risk of schizophrenia: a pathway analysis of GWAS data. Schizophr Res 2010; 122:38–42
Information & Authors
Information
Published In
History
Received: 25 October 2013
Revision received: 30 April 2014
Revision received: 21 August 2014
Revision received: 10 September 2014
Accepted: 12 September 2014
Published online: 23 January 2015
Published in print: May 01, 2015
Authors
Funding Information
National Institute of Mental Health10.13039/100000025: 2R44 MH075481, R01 MH077851, R01 MH077852, R01 MH077862, R01 MH077945, R01 MH078113
Supported by NIMH grants R01 MH077851 to Dr. Pearlson, MH078113 to Dr. Tamminga, MH077945 to Dr. Keshavan, MH077862 to Dr. Sweeney, and MH077852 to Dr. Gunavant Thaker. Additional support includes NIMH grants 2R44 MH075481 to Dr. Ruaño and NIH grants P20GM1034672 and R01EB006841 to Dr. Calhoun.Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).